Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Observational 3Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 10Myeloproliferative Disorders 6Multiple Myeloma 6Lymphoma, Mantle-Cell 6Lymphoma, Follicular 6Lymphoma, B-Cell, Marginal Zone 6Leukemia 6Congenital Abnormalities 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Waldenstrom Macroglobulinemia 4Lymphoma, Non-Hodgkin 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Acute 4Burkitt Lymphoma 4Squamous Cell Carcinoma of Head and Neck 3Sezary Syndrome 3Rectal Neoplasms 3Mycosis Fungoides 3Melanoma 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Extranodal NK-T-Cell 3Leukemia, Myeloid, Accelerated Phase 3Hodgkin Disease 3Head and Neck Neoplasms 3Colonic Neoplasms 3Breast Neoplasms 3Blast Crisis 3

Interventions

Carboplatin 340Cisplatin 238Paclitaxel 203Radiotherapy 195Pemetrexed 187Docetaxel 169Gemcitabine 157pembrolizumab 141Erlotinib Hydrochloride 107Etoposide 99Magnetic Resonance Spectroscopy 93Bevacizumab 91Specimen Handling 76Nivolumab 73Radiosurgery 72durvalumab 69Vinorelbine 54osimertinib 53Gefitinib 49Drug Therapy 49atezolizumab 42Irinotecan 42Radiation 40Topotecan 39Biopsy 39Standard of Care 38Cyclophosphamide 38Cetuximab 35Blood Specimen Collection 33Taxes 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lung Neoplasms × In Situ Hybridization, Fluorescence × Clear all
NCT00989690 2013-08-12

Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
275 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡